Prevalence, incidence and characteristics of the metabolic syndrome (MetS) in a cohort of Mexican Mestizo early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between MetS and disease activity

Table 7 Regression models to define predictors for sustained remission

	Model 1 (parsimonious)	Model 2	Model 3
DAS28 at baseline	0.44, 023 to 0.85	0.50, 0.21 to 0.85	0.42, 0.21 to 0.85
Incidental MetS	0.23, 0.05 to 1.00	0.18, 0.04 to 0.89	0.23, 0.05 to 1.09
Disease duration at baseline		1.28, 0.94 to 1.74	1.26, 0.93 to 1.70
ACCP		0.20, 0.02 to 2.29
Age			0.97, 0.90 to 1.04

Data presented as Exp (β), 95% confidence interval. ACCP, antibodies to cyclic citrullinated peptides; DAS28, disease activity score evaluated in 28 joints; MetS, metabolic syndrome.

ISSN: 1478-6362